DelSiTech is pleased to announce our participation in the Swiss Nordic BIO high-level partnering and investor conference to be held from the 10-11th of February 2021 at 9:00am CET.
Swiss Nordic BIO is a unique event in so much that it focuses on providing a connection specifically between Swiss and Nordic pharmaceutical industry innovators and investors. Silica Matrix, DelSiTech’s core technology platform and the basis for lead internal assets, has seen evermore widespread use, in the development of evermore critical medical interventions over the last several years with prominent partners. As a result, DelSiTech is proud to report significant year-on-year growth and has enjoyed a perpetual scale-up of operations, including enhancing of development capacity and introducing new leading capabilities to our list of proficiencies. DelSiTech as a private entity has reached a state of maturity, where an enhanced strategy for future growth is warranted and subsequently DelSiTech will be attending the event to meet with investors to discuss pre-IPO funding opportunities.
Are you interested in meeting us during Swiss Nordic BIO? Reach out to us here to schedule a meeting.